Insider Selling: Neurocrine Biosciences, Inc. (NBIX) CEO Sells 3,750 Shares of Stock
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) CEO Kevin Charles Gorman sold 3,750 shares of Neurocrine Biosciences stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $78.89, for a total transaction of $295,837.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Shares of Neurocrine Biosciences, Inc. (NASDAQ NBIX) opened at $80.68 on Friday. The company has a debt-to-equity ratio of 1.05, a quick ratio of 14.37 and a current ratio of 14.38. Neurocrine Biosciences, Inc. has a one year low of $38.43 and a one year high of $83.84.
Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings data on Wednesday, November 1st. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.36. The business had revenue of $60.77 million during the quarter, compared to the consensus estimate of $29.38 million. During the same period in the prior year, the firm earned ($0.43) EPS. sell-side analysts expect that Neurocrine Biosciences, Inc. will post -1.59 EPS for the current year.
A number of analysts have weighed in on NBIX shares. Jefferies Group reaffirmed a “buy” rating and set a $69.00 target price (up previously from $66.00) on shares of Neurocrine Biosciences in a research note on Tuesday, October 3rd. BMO Capital Markets reaffirmed an “outperform” rating and set a $84.00 target price on shares of Neurocrine Biosciences in a research note on Thursday, October 5th. Leerink Swann reaffirmed an “outperform” rating and set a $72.00 target price (up previously from $67.00) on shares of Neurocrine Biosciences in a research note on Tuesday, October 10th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $76.00 target price on shares of Neurocrine Biosciences in a research note on Wednesday, October 25th. Finally, Citigroup reaffirmed a “buy” rating and set a $79.00 target price on shares of Neurocrine Biosciences in a research note on Thursday, November 2nd. One research analyst has rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $82.31.
ILLEGAL ACTIVITY WARNING: “Insider Selling: Neurocrine Biosciences, Inc. (NBIX) CEO Sells 3,750 Shares of Stock” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://www.thecerbatgem.com/2018/01/21/insider-selling-neurocrine-biosciences-inc-nbix-ceo-sells-3750-shares-of-stock.html.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.